Systemic sclerosis (SSc, or scleroderma), is a chronic, progressive, autoimmune disease characterized by inflammation and fibrosis of connective tissues throughout the body, including the skin and internal organs. SSc that occurs in the lungs is called SSc-related interstitial lung disease (SSc-ILD).
We are investigating whether an investigational drug, called efzofitimod, can improve (or be an effective form of treatment for) the skin and lung effects caused by SSc-ILD. The clinical trial investigating efzofitimod for the treatment of SSc-ILD is called the EFZO-CONNECT™ Study.
If you are interested in taking part in this clinical trial for SSc-ILD, we are looking for people who:
- Are ≥ 18 years of age
- Have a diagnosis of SSc-ILD
- Have a duration of systemic scleroderma < 6 years since your first non-Raynaud’s (i.e., non-skin) symptom
- Have been taking mycophenolate mofetil (MMF) of ≥ 2 gm/day for at least 6 months, or if not on MMF, you are on a different immunosuppressant for SSc-ILD